L. Bergman

MRSI correlates of cognitive–behavioral therapy in pediatric obsessive–compulsive disorder

N. Salamon, J. Alger, J. McCracken, 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.

J. McCracken, P. Kendall, J. Piacentini, 2011, Journal of consulting and clinical psychology.

Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.

D. Pine, L. Ritz, J. McCracken, 2001, The New England journal of medicine.

Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial

S. Posse, N. Salamon, J. Alger, 2017, Neuropsychopharmacology.

Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders.

Sabine Hack, Michael Sweeney, John Piacentini, 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties.

L. Ritz, L. Greenhill, M. Davies, 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

Clinical characteristics of anxiety disordered youth.

Golda S. Ginsburg, J. McCracken, C. Suveg, 2010, Journal of anxiety disorders.

Predicting Anxiety Diagnoses and Severity with the CBCL-A: Improvement Relative to Other CBCL Scales?

J. McCracken, C. Suveg, P. Kendall, 2015, Journal of psychopathology and behavioral assessment.

Predicting Anxiety Diagnoses and Severity with the CBCL-A: Improvement Relative to Other CBCL Scales?

J. McCracken, C. Suveg, P. Kendall, 2014, Journal of Psychopathology and Behavioral Assessment.